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Symposium on hilar cholangiocarcinoma
Hilar cholangiocarcinoma has been a subject of major interest in the IHPBA ever since its founding, with many
members who have emerged as leading experts in the management of this difficult tumour. This thematic issue of
HPB addresses some of the current issues in the surgical treatment of hilar cholangiocarcinoma.
The first contribution, from New York, deals with preoperative evaluation and assessment of resectability of
hilar cholangiocarcinoma. The Bismuth–Corlette classification is based on proximal extent of the tumour into the
biliary tree, but does not take into account vascular involvement. The authors therefore propose an alternative,
clinical staging system based on biliary ductal involvement, vascular involvement and lobar atrophy. The paper
from Paris points out the need for optimal preoperative preparation of patients with hilar cholangiocarcinoma
considered for resection. Although preoperative biliary decompression is controversial, it probably is important in
patients with hilar cholangiocarcinoma requiring extended liver resection in order to allow postoperative or
preoperative regeneration of the liver, the latter in the setting of preoperative portal vein embolization to induce
hypertrophy of the future liver remnant.
Resectional strategies in the treatment of hilar cholangiocarcinoma are discussed in the contribution from
Houston. Resection of the portal vein bifurcation in conjunction with hilar resection potentially increases the rate
ofmargin-negative resections, but as the authors emphasize, is not routinely recommended in the absence of signs
of portal vein invasion. The authors from Nagoya, who pioneered resection of hilar cholangiocarcinoma with
extended liver resections three decades ago, show that in recent years, thesemajor resections have been performed
with a mortality rate of55% and a 5-year survival rate of 27% (in R0 resections). They also show that patients
resected with regional lymph node metastases still have a better survival than unresected patients. In a study from
Amsterdam, it is shown that complete excision of segment 1 with resection of hilar cholangiocarcinoma leads to a
higher rate of R0 resections and improves survival without increasingmorbidity ormortality. The current status of
liver transplantation in the treatment of hilar cholangiocarcinoma is reviewed in the paper from Essen. The place
of liver transplantation needs to be reconsidered in the light of recent, promising results of neoadjuvant therapies
in selected patients.
Surgical palliative treatment of hilar cholangiocarcinoma is addressed in the contribution from Edinburgh.
Relief of pruritus or cholangitis is the main indication for biliary drainage, and most experience to date concerns
segment III cholangio-jejunostomy as a biliary bypass procedure. Although favourable results have been reported
for intrahepatic ductal bypass, it remains to be seen whether these procedures can compete with percutaneous
stenting techniques. A review from Indianapolis addresses the role of radiation and chemotherapy in hilar
cholangiocarcinoma. Whereas the benefit of radiation or chemotherapy alone is questionable, chemoradiation
seems the way to go but awaits further clinical assessment in controlled trials.
It gives the editors of HPB great pleasure to present in this issue a true update on the surgical management of
hilar cholangiocarcinoma, at the same time showing the vast experience with this tumour shared in the IHPBA.
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